Analysis of the tumor biological factor regulating the antibody-delivery

胰腺癌作为一种难治性实体瘤，肿瘤间质屏障干扰了抗体的传递。为了提高抗体药物结合物(ADC)对这类肿瘤的转运能力和最大的治疗效果，必须确定最合适的药物设计，如抗基质抗体与细胞外药物释放连接物的结合。另一方面，细胞靶向ADC对恶性淋巴瘤是有效的，因为它是一种间质贫乏的肿瘤，不受抗体传递的干扰。在这种类型的ADC中，应该选择具有高细胞内化效率的抗体。

In pancreatic cancer as a refractory solid tumor, tumor stromal barrier interferes with antibody-delivery. To improve the delivery and maximize the therapeutic effect of antibody drug conjugate (ADC) against such tumors, it is important to determine the most appropriate drug design e.g. combination of the anti-stroma antibody and the linker for the drug-release outside the cells. On the other hand, cell-targeting ADC is effective against malignant lymphoma as a stroma-poor tumor without the interference of antibody-delivery. In this type of ADC, an antibody having a high cell-internalization efficacy should be selected.